Expert bioPaolo Ghia received his MD from the University of Torino, Italy, followed by a residency in Internal Medicine. He received his PhD working at the Basel Institute for Immunology, Basel, Switzerland, where he studied the development of normal human B lymphocytes. He moved to the Dana-Farber Cancer Institute, Harvard Medical School, Boston, where he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma.
He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the Ospedale San Raffaele. He is Head of the Laboratory of B-Cell Neoplasia and Director of the Strategic Research Program on CLL, where he is National Coordinator or Principal Investigator in clinical trials in CLL and related disorders, including phase 1 studies.
His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL). On these topics he has published over 240 manuscripts in peer-reviewed journals.
He is President of the European Research Initiative on CLL (ERIC), collaborating to the guidelines for the detection of Minimal Residual Disease (MRD) for the analysis of the mutational status of the immunoglobulin (IGHV) genes and of the TP53 gene aberrations. He is also a member of the International Workshop on CLL (iwCLL) and of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic Malignancies for the topic Chronic Lymphocytic Leukemia, MBL, and PLL. He coauthors the EHA-ESMO guidelines for CLL treatment. He is currently Associate Editor for CLL at Hemasphere, the official Journal of the European Hematology Association (EHA).